Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in San Sebastian De Los Reyes – page 265

3 196 clinical trials in San Sebastian De Los Reyes, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
San Sebastian De Los Reyes at a glance
3 196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 196 trials in San Sebastian De Los Reyes

Open in trial search

Breast cancer metastatic+1

Not recruiting

Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Colorectal cancer metastatic

Not recruiting

Study on Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Associacio Per A La Recerca Oncologica

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Age-related macular degeneration

Not recruiting

Study on the Effectiveness of Bevacizumab and Ranibizumab in Treating Age-Related Macular Degeneration in Patients with Genetic Variations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Hormone-refractory prostate cancer

Not recruiting

Study Comparing Docetaxel Alone and Docetaxel with Radium-223 for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Radium RA 223 dichloride
  • Sponsor:Memorial Sloan Kettering Cancer Center

Myelofibrosis+1

Not recruiting

Study of Selinexor for Patients with Previously Treated Myelofibrosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Selinexor
  • Sponsor:Karyopharm Therapeutics Inc.

Bladder cancer

Not recruiting

Study of Sasanlimab and Sacituzumab Govitecan for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab
  • Sponsor:Associacio Per A La Recerca Oncologica

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Major depression

Not recruiting

Study on Aticaprant for Adults with Major Depressive Disorder and Anhedonia Not Responding to Antidepressants

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Cardiac failure+4

Not recruiting

Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:CDR132L
  • Sponsor:Cardior Pharmaceuticals GmbH

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in San Sebastian De Los Reyes

What the registry says about research in the country

01 Immunology & Allergies

Research focusing on innovative treatments for allergic rhinoconjunctivitis and immune system disorders. Studies include testing immunotherapy effectiveness using specific allergen proteins.

  • Allergic Rhinoconjunctivitis
  • Atopic Dermatitis
  • Myasthenia Gravis

Trials evaluate novel therapeutic approaches for autoimmune conditions and allergic responses.

02 Cardiovascular Health

Comprehensive studies addressing various cardiovascular conditions, including deep vein thrombosis and heart failure management.

  • Pulmonary Embolism
  • Atherosclerotic Disease
  • Hypercholesterolemia

Research focuses on innovative treatments and preventive approaches for cardiovascular complications.

03 Oncology Research

Advanced clinical trials investigating treatments for various cancer types, with emphasis on ovarian cancer and breast cancer therapies.

  • Epithelial Ovarian Cancer
  • HER2+ Breast Cancer
  • Endometrial Cancer

Studies evaluate targeted therapies and maintenance treatments for cancer patients.

04 Metabolic & Systemic Disorders

Research examining treatments for systemic lupus erythematosus and metabolic conditions affecting multiple body systems.

  • Obesity Management
  • Diabetic Neuropathy
  • Liver Disease

Trials focus on innovative therapeutic approaches for chronic systemic conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.